P16-32. Antigen exposure regulates the balance between proliferating and cytotoxic subsets of virus-specific CD8 T-cells by Harari A, Pantaleo G, Bart P, Enders F, Rozot V, Perreau M, Cellerai C

P16-48. Immunologic and virologic characterization of an ART-treated HIV-1 patients cohort with long-term control of viremia by Harari A, Johnson A, Stauss H, Carroll A, Byrne P, Yerly S, Cellerai C, Kinloch S, Pantaleo G

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C by Gómez C, Perdiguero B, Jimenez V, Filali-Mouhim A, Ghneim K, Haddad E, Quakkerlaar E, Delaloye J, Harari A, Roger T, Duhem T, Sekaly R, Melief C, Calandra T, Sallusto F, Lanzavecchia A, Wagner R, Pantaleo G, Esteban M

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. by Bart, P, Goodall, R, Barber, T, Harari, A, Guimaraes-Walker, A, Khonkarly, M, Sheppard, N, Bangala, Y, Frachette, M, Wagner, R, Liljeström, P, Kraehenbuhl, J, Girard, M, Goudsmit, J, Esteban, M, Heeney, J, Sattentau, Q, McCormack, S, Babiker, A, Pantaleo, G, Weber, J